Halozyme Fair Value
RV
The fair market value of RV7.DU stock is 58.34 EUR. Relative to the market price of 43.55 EUR Halozyme is undervalued by 34.7%
Eyestock's quantitative valuation approach is based on the method of estimating historical multipliers. To determine whether a stock is undervalued, we compare its current price to our estimated of fair value. The more undervalued a stock is, the more investment is profitable.
Fair Relative Value
Halozyme Valuation
Current RV7.DU share ticker price is 43.55 EUR.
The fair value level of 58.34 EUR can be considered as an effective entry point for long-term investors to start investing in RV7.DU stock. For a more in-depth assessment, we provide a minimum value that can be used to increase a stock position and a maximum one that can be used to reduce it.
Price chart is not available
Current market price
Current price is 34% lower its fair value
Current price is 5% higher its minimum value
Current price is 157% lower its maximum value
Market price:
RV7.DU stock is undervalued
It means the current price may concern as a Moderate Risk Entry Point
Halozyme Therapeutics Inc Stock Valuation Calculator
How do we value a stock?
As fair value, we use the product of the median Price-to-earnings ratios at the end of each reporting period for the last 5 years and earnings per share for the last 12 months. By analogy with the fair value, we calculate the maximum and minimum ones using the corresponding P/E extremums.
1
Maximum P/E over 5 years
38.07
2
Median P/E over 5 years
19.85
3
Minimum P/E over 5 years
14.15
4
Earning per share (last 12 months)
3.07 USD
Maximum value
1
x
4
=
111.89 EUR
Fair value
2
x
4
=
58.34 EUR
Minimum value
3
x
4
=
41.59 EUR
Halozyme Therapeutics Inc price metrics
19.33
Annual return (geometric mean)
41.42
Risk (standard deviation) of returns
β
1.31
Beta (volatility compared to market)